The Quantellect read.As of Nov 19, 2026, 20 active firms cover Ionis Pharmaceuticals Inc: 16 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $54.00 to $129.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $89.63 sits 227% above the current $27.44. The rating mix has stayed broadly stable, with Buy-side ratings easing from 17 to 16 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.81 next quarter toward $-2.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Buy
Strong Buy00%
Buy1680%
Neutral420%
Sell00%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$89.63
+226.6% upside
Average target across 19 active firms as of Nov 19, 2026 vs $27.44 current
Highest Target$129.00
Average Target$89.63
Lowest Target$54.00
Detailed analyst forecasts for IONS
Showing 1–21 of 21 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 16 of 20 active firms rate IONS a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IONS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.81
Range $-0.84 – $-0.76 · 3 analysts · +166% YoY
Next period, 3 analysts expect Ionis Pharmaceuticals Inc to earn $-0.81 a share (range $-0.84 – $-0.76), versus $-0.30 a year earlier. Full-year consensus is $-2.42, growing to $-2.03 the year after.
REVENUE · NEXT QUARTER
$244.4M
Range $147.6M – $337.4M · 3 analysts · -1% YoY
Revenue is expected to reach $244.4M (range $147.6M – $337.4M), -0.7% year-over-year. Full-year consensus is $920.1M, rising to $1.2B next year.
Top analysts covering Ionis Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IONS.
#1
Luca Issi
RBC Capital · Rank #76
Buy
$60.00+118.7% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Buy
$70.00+155.1% to target
Overall win rate
54%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #160
Buy
$63.00+129.6% to target
Overall win rate
47%
+ Follow
#4
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$80.00+191.5% to target
Overall win rate
39%
+ Follow
#5
Joseph Stringer
Needham · Rank #256
Buy
$86.00+213.4% to target
Overall win rate
36%
+ Follow
IONS stock forecast FAQ
What is IONS's average 12-month price target?+
The 19 active firms with a live target average $89.63 for Ionis Pharmaceuticals Inc over the next 12 months, ranging from a $129.00 high to a $54.00 low, as of Nov 19, 2026.
Is IONS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 20 active firms as of Nov 19, 2026, 16 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IONS?+
The Street-high target is $129.00 (Leerink Partners), and the Street-low is $54.00 (BMO Capital). The average of all 19 active-firm targets is $89.63.
How many active Wall Street firms cover IONS?+
20 active firms have a recognized rating on Ionis Pharmaceuticals Inc as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IONS?+
Among analysts who currently cover IONS, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #76). Their current call is Buy with a $60.00 target.
What is Ionis Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.81 per share (range $-0.84 – $-0.76) across 3 analysts. Full-year EPS is projected at $-2.42, rising to $-2.03 the following year.
How much revenue is Ionis Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $244.4M (range $147.6M – $337.4M). Full-year revenue is projected at $920.1M, growing to $1.2B next year.
Have analysts been upgrading or downgrading IONS lately?+
As of Nov 19, 2026, 16 of 20 active firms rate IONS a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IONS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.